Journal article

Panton-Valentine Leukocidin Is Not the Primary Determinant of Outcome for Staphylococcus aureus Skin Infections: Evaluation from the CANVAS Studies

Amy Tong, Steven YC Tong, Yurong Zhang, Supaporn Lamlertthon, Batu K Sharma-Kuinkel, Thomas Rude, Sun Hee Ahn, Felicia Ruffin, Lily Llorens, Ganesh Tamarana, Donald Biek, Ian Critchley, Vance G Fowler

PLoS One | PUBLIC LIBRARY SCIENCE | Published : 2012

University of Melbourne Researchers

Grants

Awarded by Australian National Health and Medical Research Council Postdoctoral Training Fellowship



Awarded by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES


Funding Acknowledgements

V.G.F. was supported in part by K24-AI093969 (http://grants.nih.gov/) .S.Y.C.T. was supported by an Australian National Health and Medical Research Council Postdoctoral Training Fellowship (508829) (http://www.nhmrc.gov.au/grants), an Australian-American Fulbright Scholarship and a Royal Australasian College of Physicians Bayer Australia Medical Research Fellowship. This work was supported by Cerexa, Inc., Oakland, CA, (http://www.cerexa.com/) wholly owned subsidiary of Forest Laboratories, Inc. (New York, NY). The CANVAS clinical program was funded by Forest Laboratories, Inc., New York, NY. Forest Laboratories, Inc., was involved in the design, collection, analysis, and decision to present these results. Forest Laboratories, Inc., had no involvement in the interpretation of the data. Scientific Therapeutics Information, Inc., provided editorial coordination, which was funded by Forest Research Institute, Inc. Laboratory isolates were obtained from Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA).L.L., G.T., D.B., and I.C. are employees of Cerexa, Inc. V.G.F. has received grants or research support from Astellas Pharma, Inc., Cubist Pharmaceuticals, Merck & Co., Inc., Theravance, Inc., MedImmune, Cerexa, Inc., Pfizer, and the United States National Institutes of Health. He is a consultant for Astellas Pharma, Inc., Biosynexus, Novartis, Cubist Pharmaceuticals, Inimex, Merck & Co., Inc., Galderma, Johnson & Johnson, Medicines Company, Novartis and is on the speaker's bureau and advisory committee for Cubist Pharmaceuticals. He has received honoraria from Achaogen, Arpida, Astellas Pharma, Inc., Cubist Pharmaceuticals, Durata, Inhibitex, Leo Pharma, Merck & Co., Inc., Pfizer, Targanta, Theravance, Inc., and Ortho-McNeil. Scientific Therapeutics Information, Inc., provided editorial coordination (which was funded by Forest Research Institute, Inc.). A.T., S.Y.C.T., Y.Z., S.L., B.K.S., T.R., and F.R. have no competing interests to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.